Your browser doesn't support javascript.
loading
Reappraisal of Grading in Intestinal-Type Sinonasal Adenocarcinoma: Tumor Budding as an Independent Prognostic Parameter.
Meerwein, Christian M; Brada, Muriel D; Soyka, Michael B; Holzmann, David; Rupp, Niels J.
Afiliação
  • Meerwein CM; Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital of Zurich and University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland. christian.meerwein@usz.ch.
  • Brada MD; Department of Molecular Pathology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.
  • Soyka MB; Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital of Zurich and University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
  • Holzmann D; Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital of Zurich and University of Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
  • Rupp NJ; Department of Molecular Pathology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.
Head Neck Pathol ; 16(3): 670-678, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35015192
ABSTRACT
Since sinonasal intestinal-type adenocarcinomas (ITAC) show resemblance to colorectal adenocarcinomas, we aimed to investigate novel prognostic factors of outcome, with particular focus on the role of tumor budding (TB). Retrospective clinico-pathological single-institution study on consecutive ITAC patients between 1996 and 2020. Histopathological parameters including conventional subtypes and TB features (low, intermediate, high) were evaluated with the aid of pancytokeratin (AE1/AE3) immunohistochemical staining. Parameters were correlated to clinical data and outcome. A total of 31 ITAC patients were included. Overall, 19/31 patients (61.3%) presented with stage III/IV disease. Presence of lymph node or distant metastases was rare (1/31 patient, 3.2%). Treatment protocols consisted of tumor resection in 30/31 patients (96.8%) and primary radiochemotherapy in 1/31 patient (3.2%). Adjuvant radiation therapy was conducted in 20/30 surgically treated patients (66.7%). The 3- and 5-year overall survival (OS) was 83.9% and 78.3% and the 3- and 5-years disease-specific survival (DSS) 83.7% % and 78.5%, respectively. The presence of intermediate/high TB (defined as ≥ 5 buds) was associated with both, worse DSS (log rank p = 0.03) and OS (log rank p = 0.006). No patient with low TB revealed progressive disease or died of the disease. No association between TB and tumor stage or conventional tumor subtype was found. Tumor budding seems to be an independent prognostic factor of worse outcome in ITAC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Colon_e_reto Base de dados: MEDLINE Assunto principal: Neoplasias dos Seios Paranasais / Neoplasias Colorretais / Adenocarcinoma Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Head Neck Pathol Assunto da revista: NEOPLASIAS / PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Colon_e_reto Base de dados: MEDLINE Assunto principal: Neoplasias dos Seios Paranasais / Neoplasias Colorretais / Adenocarcinoma Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Head Neck Pathol Assunto da revista: NEOPLASIAS / PATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça